About Enhancer
| Enhancer ID: | E_02160 |
| Species: | Homo sapiens |
| Position : | chr14:36980000-36983000   |
| Year: | 2025 |
| Title: | NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | prostate cancer |
| PMID: | 40691407 |
| MONDO: | MONDO:0008315 |
| Tissue: | prostate gland |
| Tissue Ontology ID: | UBERON:0002367 |
| Cell Source: | LuCaP93 PDX |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| High Throughput Method: | FOXA2 ChIP-seq; H3K27ac ChIP-seq; Hi-C; ATAC-seq |
| Low Throughput Method: | CRISPR perturbation; qRT-PCR; Western blot |
About Target Gene
| Target gene : | NKX2-1 |
About TF
| TF name : | FOXA2 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| FOXA2 | FOXA1 transcription factor network | pid | 45 |
| FOXA2 | FOXA2 and FOXA3 transcription factor networks | pid | 45 |
| FOXA2 | Hedgehog signaling events mediated by Gli proteins | pid | 49 |
| FOXA2 | Regulation of gene expression in beta cells | reactome | 17 |
| FOXA2 | Maturity onset diabetes of the young | kegg | 25 |
| FOXA2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| FOXA2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| FOXA2 | Hs_Heart_Development_WP1591_90186 | wikipathways | 28 |
| FOXA2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |
Enhancer Associated Network
Overlapping Enhancers (hg38)
No overlapping enhancers found in hg38 at this locus.
Expression of Target Genes for the Enhancer